Adicet Bio's Prula-cel Shines in Lupus Trial, Offers Hope for 'One-and-Done' Treatment

Adicet Bio has announced groundbreaking positive safety and efficacy results from its Phase 1 study of Prula-cel, an 'off-the-shelf' CAR T-cell therapy, for patients suffering from Systemic Lupus Erythematosus (SLE) with or without Lupus Nephritis (LN). The data, as of August 28, 2026, revealed that 54% of evaluable patients achieved DORIS remission at 12 months, with 50% of lupus nephritis patients reaching a complete renal response, offering a potential paradigm shift towards a single, lasting treatment for this debilitating autoimmune disease. Crucially, almost all patients in the heavily pretreated group were able to discontinue or significantly reduce their reliance on chronic immunosuppressants and steroids. The promising data comes at a critical time when other CAR T-cell therapies repurposed for autoimmune conditions have faced significant safety concerns, including serious immune reactions like cytokine release syndrome (CRS) and neurotoxicity. Adicet's Prula-cel, which leverages a unique allogeneic gamma delta T-cell approach, demonstrated a favorable safety profile with no cases of severe CRS, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), setting it apart in the competitive landscape. This unique cell type is believed to contribute to a milder side effect profile while still effectively 'resetting' the immune system by targeting B cells. Looking ahead, Adicet Bio plans to initiate start-up activities for a pivotal study in lupus nephritis during the fourth quarter of 2026, with potential discussions with the FDA to expand this study to include lupus patients without kidney involvement. If successful, Prula-cel could revolutionize the treatment landscape for millions suffering from autoimmune diseases, moving away from a lifetime of chronic medication to a one-time therapy that achieves durable, treatment-free remission and significantly improves patient quality of life. The biotech world will be watching closely as these next-stage trials unfold.